{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:57Z","timestamp":1759366077239,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nefro.2019.04.012","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T17:19:26Z","timestamp":1566580766000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progresi\u00f3n de la enfermedad renal cr\u00f3nica en pacientes con hipertensi\u00f3n resistente sometidos a 2 estrategias terap\u00e9uticas: intensificaci\u00f3n con diur\u00e9ticos de asa vs. antagonistas de la aldosterona"],"prefix":"10.1016","volume":"40","author":[{"given":"U.","family":"Verdalles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Garc\u00eda de Vinuesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Verde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"P\u00e9rez de Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.04.012_bib0140","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.04.012_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.109.129841","article-title":"Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006","volume":"54","author":"Plantinga","year":"2009","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.04.012_bib0150","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.nefro.2019.04.012_bib0155","first-page":"4","article-title":"Presi\u00f3n arterial y progresi\u00f3n de la enfermedad renal cr\u00f3nica","volume":"5","author":"Santamaria-Olmo","year":"2013","journal-title":"Nefroplus"},{"key":"10.1016\/j.nefro.2019.04.012_bib0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/nep.12475","article-title":"Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?","volume":"20","author":"Verdalles","year":"2015","journal-title":"J Nephrology."},{"key":"10.1016\/j.nefro.2019.04.012_bib0165","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension."},{"issue":"Suppl 4","key":"10.1016\/j.nefro.2019.04.012_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/gfs420","article-title":"Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD)","volume":"27","author":"Verdalles","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.04.012_bib0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.nefro.2019.04.012_bib0180","first-page":"510","article-title":"Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"24","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2019.04.012_bib0185","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"31","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.nefro.2019.04.012_bib0190","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ndt\/gfp534","article-title":"Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension","volume":"25","author":"Hanratty","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.04.012_bib0195","doi-asserted-by":"crossref","first-page":"e0146056","DOI":"10.1371\/journal.pone.0146056","article-title":"Kidney function decline and apparent treatment-resistant hypertension in the elderly","volume":"25","author":"Kabor\u00e9","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2019.04.012_bib0200","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1053\/j.ajkd.2010.06.010","article-title":"Factors associated with kidney disease progression and mortality in a referred CKD population","volume":"56","author":"Hoefield","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2019.04.012_bib0205","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2215\/CJN.01180211","article-title":"Prognosis of CKD patients receiving outpatient nephrology care in Italy","volume":"6","author":"De Nicola","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.04.012_bib0210","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2215\/CJN.08590910","article-title":"Development and validation of a general population renal risk score","volume":"6","author":"Halbesma","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.04.012_bib0215","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: A multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.nefro.2019.04.012_bib0220","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.04.012_bib0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000290","article-title":"Mineralocorticoid antagonists in chronic kidney disease","volume":"26","author":"Dhaybi OA1","year":"2017","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2019.04.012_bib0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ajh\/hpw105","article-title":"Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension","volume":"30","author":"Dudenbostel","year":"2017","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.nefro.2019.04.012_bib0235","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3109\/0886022X.2014.917560","article-title":"Diuretics associated acute kidney injury: Clinical and pathological analysis","volume":"36","author":"Wu","year":"2014","journal-title":"Ren Fail."},{"key":"10.1016\/j.nefro.2019.04.012_bib0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1889-1837(01)71796-5","article-title":"[Renal function impairment with angiotensin converting enzyme inhibitors]","volume":"18","author":"Alc\u00e1zar de la Ossa","year":"2001","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.nefro.2019.04.012_bib0245","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10157-014-0981-2","article-title":"Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease","volume":"19","author":"Hoshino","year":"2015","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.nefro.2019.04.012_bib0250","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2015.249","article-title":"Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease","volume":"88","author":"Morales","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.04.012_bib0255","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"21","author":"Williams","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2019.04.012_bib0260","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2215\/CJN.07460713","article-title":"Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy","volume":"9","author":"Van Buren","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.04.012_bib0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.04.012_bib0270","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","article-title":"Metabolic complications associated with use of diuretics","volume":"31","author":"Palmer","year":"2011","journal-title":"Semin Nephrol."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519301225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519301225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:54:55Z","timestamp":1759323295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519301225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0211699519301225"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.04.012","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progresi\u00f3n de la enfermedad renal cr\u00f3nica en pacientes con hipertensi\u00f3n resistente sometidos a 2 estrategias terap\u00e9uticas: intensificaci\u00f3n con diur\u00e9ticos de asa vs. antagonistas de la aldosterona","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}